Table 2.

Antibody concentrations above the indicated thresholds 1 month after a 3-dose 7vCRM primary vaccinationa

Serotype% Vaccine effectiveness (95% CI) in the U.S. (41)% of subjects (95% CI) with ELISA-determined antibody concn of:
≥0.2 μg/ml≥0.35 μg/ml≥0.5 μg/ml≥1.0 μg/ml
Vaccine serotypes
    493 (65–99)100 (99.6–100)99.5 (98.8–99.9)99.4 (98.6–99.8)93.7 (91.9–95.2)
    6B94 (77–98)87.1 (84.7–89.3)80.8 (78.0–83.4)75.1 (72.0;78.0)55.2 (51.8–58.6)
    9V100 (88–100)99.4 (98.6–99.8)98.6 (97.6–99.3)97.7 (96.4–98.6)93.6 (91.7–95.1)
    1494 (81–98)99.6 (99.0–99.9)98.1 (97.0–98.9)96.7 (95.3–97.8)93.2 (91.3–94.8)
    18C97 (85–99)99.2 (98.3–99.7)98.1 (97.0–98.9)97.0 (95.6–98.0)91.7 (89.7–93.5)
    19F87 (65–95)99.4 (98.6–99.8)98.5 (97.4–99.2)98.1 (97.0–98.9)94.5 (92.8–96.0)
    23F98 (80–100)95.3 (93.7–96.6)91.1 (89.0–92.9)88.1 (85.7–90.2)76.8 (73.8–79.6)
Vaccine-related serotypes
    6A76 (39–90)55.5 (51.3–59.6)41.4 (37.3–45.5)33.0 (29.1–37.0)17.6 (14.6–21.0)
    19A26 (−45 to 62)31.0 (27.2–35.0)14.5 (11.7–17.6)9.6 (7.3–12.3)2.4 (1.3–4.1)
  • a Shown are percentages of subjects (and 95% CI) with antibody concentrations above the indicated thresholds 1 month after a 3-dose 7vCRM primary vaccination for the seven pneumococcal vaccine serotypes (n = 859) and the vaccine-related serotypes 6A and 19A (n = 574) compared with serotype-specific vaccine effectiveness calculated for 7vCRM in the United States. n = number of subjects with available results pooled from studies A to D (2, 18, 37, 46). The actual number of subjects can slightly vary for the different serotypes depending on the available sera.